--- canonical_name: Luteolin alternate_names: 3',4',5,7-Tetrahydroxyflavone, Digitoflavone, Luteolol canonical_topic: Luteolin for Health & Longevity short_topic_lc: luteolin creation_date: 2026-0805-2009 creator_ai_fullname: Grok 4 --- # Luteolin for Health & Longevity

Evidence Review created on 08/05/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** 3',4',5,7-Tetrahydroxyflavone, Digitoflavone, Luteolol ## Motivation Luteolin is a yellow plant flavone found in celery, parsley, thyme, green peppers, artichoke, and olive oil. It draws interest as a dietary flavonoid with antioxidant and anti-inflammatory actions that touch brain health, immune signaling, and cellular stress defenses relevant to healthy aging. Historically used as a natural dye and present in traditional plant medicines, luteolin entered modern research for mast-cell and microglial (brain immune cell) modulation, and later for protecting brain and heart tissue in laboratory models. Human trials remain limited; the strongest clinical signal so far comes from combinations of luteolin with palmitoylethanolamide for smell recovery after viral illness and early work in neurodegenerative and inflammatory settings. Poor oral absorption has long constrained clinical use, which is why newer high-bioavailability formulations are now a focus. This review examines the evidence for luteolin as a longevity-oriented intervention: primary mechanisms, expected benefits and risks by strength of evidence, practical protocol and quality factors, and how it interacts with foundational habits. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews and expert commentary on luteolin covering mechanisms, clinical context, and formulation advances. - [Luteolin, a plant-derived antioxidant, shows promise in reducing gray hair by maintaining key cellular communication and combating follicle aging](https://www.foundmyfitness.com/stories/tum5oo/luteolin_a_plant-derived_antioxidant_shows_promise_in_reducing_gray_hair_by_maintaining_key_cellular_communication_and_combating_follicle_aging) - Rhonda Patrick FoundMyFitness science digest summarizing mouse data on oral and topical luteolin preserving communication between hair-follicle and melanocyte stem cells, useful as an accessible entry to luteolin’s anti-inflammatory and tissue-aging research. - [Vastly Improved Luteolin Bioavailability](https://www.lifeextension.com/magazine/2026/3/improved-luteolin-bioavailability) - David Novis March 2026 feature on formulation science: why standard luteolin is poorly absorbed and how a newer delivery system raised human bioavailability up to about 14-fold, with context on aging-related research claims. - [Luteolin: The wonder flavonoid](https://pubmed.ncbi.nlm.nih.gov/33856721/) - Theoharides, 2021 Editorial-style overview from a leading mast-cell researcher on luteolin’s multi-pathway anti-inflammatory and neuroprotective profile, plus the practical problems of product purity, dose accuracy, and absorption that limit research and practice. - [Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies](https://pubmed.ncbi.nlm.nih.gov/29801717/) - Aziz et al., 2018 Narrative synthesis of molecular targets—NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), AP-1 (activator protein-1), and STAT3 (signal transducer and activator of transcription 3) pathways—that underpins much of the mechanistic rationale used in later clinical and preclinical work. Four high-quality, non-duplicate sources are listed. A second Theoharides editorial on commercial product quality was omitted to keep one item per expert; its purity/formulation themes are covered in the retained Theoharides overview and in Sourcing and Quality. No substantial dedicated content from Peter Attia, Andrew Huberman, or Chris Kresser specifically on luteolin was found as of the search date. ## Grokipedia - [Luteolin](https://grokipedia.com/page/Luteolin) Structured reference entry summarizing chemistry, natural sources, and broad biological activities of the flavone; useful as a quick factual baseline before primary literature. ## Examine No dedicated Examine.com article for luteolin was found as of August 5, 2026. ## ConsumerLab - [Luteolin: Health Benefits & Safety](https://www.consumerlab.com/answers/luteolin-health-benefits-and-safety/luteolin/) Member-oriented summary of claimed uses (inflammation, cognition, cancer, heart health, post-COVID smell loss, and others), safety notes, and the gap between laboratory findings and clinical proof; useful for a consumer-lab perspective on evidence strength and product considerations. ## Systematic Reviews Systematic reviews and meta-analyses focused on luteolin (or palmitoylethanolamide–luteolin combinations) spanning clinical and preclinical evidence. - [Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies](https://pubmed.ncbi.nlm.nih.gov/37626685/) - Capra et al., 2023 Pooled five clinical studies (441 participants) of co-ultramicronized PEA (palmitoylethanolamide; an endogenous fatty acid amide with anti-inflammatory properties) plus luteolin with olfactory training; reported greater overall smell recovery versus conventional approaches alone. - [Effects of luteolin on sepsis: A comprehensive systematic review](https://pubmed.ncbi.nlm.nih.gov/36898254/) - Vajdi et al., 2023 Review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) of 33 papers on luteolin in sepsis models; emphasizes multi-pathway anti-inflammatory and immune-modulating effects, almost entirely from non-clinical data. - [Cardioprotective Effects and Possible Mechanisms of Luteolin for Myocardial Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis of Preclinical Evidence](https://pubmed.ncbi.nlm.nih.gov/35548432/) - Pan et al., 2022 Meta-analysis of animal myocardial ischemia–reperfusion studies showing reduced infarct size and improved hemodynamics, with apoptosis, oxidative stress, and inflammation pathways implicated. - [Role of microRNAs in the anticancer effects of the flavonoid luteolin: a systematic review](https://pubmed.ncbi.nlm.nih.gov/33720053/) - Mishan et al., 2021 Synthesis of how luteolin’s anticancer actions in experimental systems may run through microRNA networks regulating proliferation, apoptosis, and invasion. - [Preclinical evidence for luteolin in ulcerative colitis: a meta-analysis and systematic review](https://pubmed.ncbi.nlm.nih.gov/40808687/) - Feng et al., 2025 Preclinical meta-analysis on colitis models supporting anti-inflammatory and barrier-protective signals that motivate future human IBD (inflammatory bowel disease) work. ## Mechanism of Action Luteolin is a tetrahydroxyflavone that acts primarily as a multi-target anti-inflammatory and antioxidant molecule rather than a single-receptor drug. - **NF-κB and AP-1 dampening:** Limits activation of NF-κB and AP-1, transcription programs that drive many inflammatory cytokines (e.g., TNF-α [tumor necrosis factor-alpha], IL-6 [interleukin-6], and IL-1β [interleukin-1 beta]). - **STAT3 / SOCS3 and MAPK pathways:** Modulates STAT3 and SOCS3 (suppressor of cytokine signaling 3; a brake on cytokine signaling) and mitogen-activated protein kinase (MAPK) cascades that couple cellular stress to immune gene expression. - **Mast-cell and microglial restraint:** Stabilizes mast cells (immune cells that release histamine and inflammatory mediators) and quiets microglia (the brain’s resident immune cells), a dual action central to proposed benefits for “brain fog,” neuroinflammation, and allergy-linked symptoms. - **Nrf2 / antioxidant defense:** Can engage the Nrf2–Keap1 pathway (nuclear factor erythroid 2–related factor 2 paired with Kelch-like ECH-associated protein 1; a master switch for cellular antioxidant enzymes), supporting endogenous defenses against oxidative stress. - **Metabolic and longevity-adjacent signaling:** Preclinical work links luteolin to AMPK (AMP-activated protein kinase; a cellular energy sensor), mitochondrial biogenesis, and reduced metabolic inflammation (“metaflammation”), though human confirmation is sparse. - **Oncology-related axes (preclinical):** Influences cell-cycle checkpoints, apoptosis, autophagy, and selected microRNAs in cancer models; clinical anticancer efficacy is unproven. **Key pharmacological properties (oral use):** - **Half-life:** Human and rodent data typically place elimination half-life roughly in the 1–7 hour range depending on formulation and free vs. conjugated fractions; most material is cleared within about a day. - **Selectivity:** Not a highly selective single-target agent; it acts on many molecular targets (polypharmacology) across kinases, transcription factors, and metabolic enzymes. - **Tissue distribution:** Parent compound and conjugates distribute widely; brain penetration is modest but cited as better than some related flavonoids, especially with liposomal/olive-oil co-formulations. - **Metabolism:** Extensive first-pass phase II metabolism (glucuronidation and sulfation via UGTs [UDP-glucuronosyltransferases; conjugation enzymes] and SULTs [sulfotransferases; sulfate-conjugation enzymes]) in intestine and liver; circulating forms are largely conjugates. In vitro inhibition of cytochrome P450 enzymes CYP3A4, CYP1A2, and CYP2C9 (drug-metabolizing enzymes that process many medications) and of OATP transporters (organic anion transporting polypeptides; membrane carriers that move drugs into cells) has been reported; clinical drug-interaction magnitude is not well quantified. Oral bioavailability of standard powder is low (often cited under ~5–10%), which is why phospholipid, liposomal, micronized, and PEA co-formulations are used. ## Historical Context & Evolution Luteolin was long known as a yellow plant pigment (from *Reseda luteola* and related dye plants) before modern pharmacology mapped its flavone structure (3′,4′,5,7-tetrahydroxyflavone). Dietary sources and traditional plant preparations containing luteolin were used for inflammatory and respiratory complaints in ethnomedicine, without isolation of the molecule as the active principle. From the late 20th century onward, cell and animal studies established antioxidant and anti-inflammatory activity. Work by Theoharides and others shifted attention to mast-cell stabilization and brain inflammation, leading to liposomal luteolin products (e.g., NeuroProtek®) studied in autism-spectrum and “brain fog” contexts. Parallel oncology and cardiology labs generated large preclinical datasets on apoptosis, ischemia–reperfusion, and metabolic disease. Interest for health optimization and longevity rose with the broader flavonoid literature (quercetin, apigenin, EGCG [epigallocatechin gallate; a green-tea catechin]) and with clinical exploration of PEA–luteolin combinations for post-viral olfactory loss and neurodegenerative conditions. Opinion has not “settled”: enthusiasm from mechanistic and PEA-combination trials coexists with repeated notes that pure luteolin human trials remain small, short, and limited by absorption. Newer high-bioavailability formulations (2020s) are an attempt to close that gap rather than a completed clinical chapter. ## Expected Benefits ### Medium 🟩 🟩 #### Post-viral olfactory recovery (as PEA–luteolin with training) Co-ultramicronized PEA plus luteolin, usually given with structured olfactory training, improved smell scores more than training or standard care alone in multiple randomized and controlled cohorts. A 2023 systematic review and meta-analysis pooled five clinical studies (441 patients) and reported significant overall recovery of olfactory function. Effects are for the combination product, not isolated luteolin monotherapy, and apply to post-COVID and related post-infectious smell loss rather than general population olfaction. **Magnitude:** Meta-analytic and trial-level improvements in threshold, discrimination, and identification scores versus control; absolute recovery rates vary by baseline severity and time since infection (not a single universal percentage). #### Neuroinflammatory symptom support (brain fog / mast-cell–linked contexts) Open-label and small controlled work with luteolin-containing or PEA–luteolin formulations has associated improvements in attention, memory complaints, and long-COVID neurocognitive symptoms with reduced inflammatory mediator signaling. Mechanisms emphasize dual mast-cell and microglial restraint. Evidence quality is medium for combination products in selected post-infectious or inflammatory phenotypes, lower for pure luteolin in healthy optimizers. Clinical series report meaningful functional gains in symptomatic groups, with high heterogeneity and without a single standardized effect size for healthy adults. **Magnitude:** Not quantified in available studies. ### Low 🟩 #### Cardioprotection (ischemia–reperfusion / oxidative cardiac stress) A systematic review and meta-analysis of animal myocardial ischemia–reperfusion models found reduced infarct size and improved left-ventricular hemodynamics with luteolin, via anti-apoptotic, antioxidant, and anti-inflammatory pathways. Human outcome trials for cardiac events or secondary prevention with luteolin are lacking. **Magnitude:** Preclinical pooled infarct-size reductions on the order of a few percentage points of left ventricle and multi–mmHg hemodynamic shifts in animal models; human magnitude unknown. #### Metabolic and glycemic support Preclinical and limited translational work suggests improved insulin signaling, reduced inflammatory markers linked to metabolic syndrome, and favorable effects on lipid and glucose handling. Dedicated large human RCTs (randomized controlled trials) of luteolin for type 2 diabetes or longevity metabolic biomarkers—such as HbA1c (glycated hemoglobin; average blood glucose over ~3 months) and HOMA-IR (homeostatic model assessment of insulin resistance; a calculated insulin-resistance index)—are not available for luteolin monotherapy. **Magnitude:** Not quantified in available studies. #### Anticancer / chemopreventive signals Extensive cell and animal data show anti-proliferative, pro-apoptotic, and anti-invasive effects, partly via microRNA networks. Systematic reviews of anticancer mechanisms exist; neither luteolin nor closely related flavones have proven clinical anticancer efficacy in controlled human trials for incidence or progression endpoints. **Magnitude:** Not quantified in available studies. #### Mast-cell–mediated allergic inflammation In vitro and animal data, plus clinical tradition with luteolin formulations in allergy-adjacent and autism-spectrum case series, support reduced mediator release from human mast cells—sometimes reported as more potent than cromolyn in culture. Controlled allergy outcome trials with validated symptom scores in typical atopic adults remain sparse. **Magnitude:** Not quantified in available studies. #### Skin inflammation and photoaging signals Narrative and mechanistic reviews describe luteolin’s ability to dampen skin inflammatory mediators and UV-linked oxidative stress in cell and animal models, with limited topical human tolerability work. Controlled trials for wrinkle depth, barrier function, or clinical dermatitis endpoints with oral or topical luteolin are sparse, so this remains a low-certainty domain relative to laboratory claims. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Longevity / healthspan extension Mechanistic links to Nrf2, AMPK, mitochondrial biogenesis, reduced chronic inflammation, and cellular senescence pathways motivate interest among longevity-oriented users. No lifespan or multi-morbidity RCTs exist in humans; any claim of extended lifespan remains speculative. #### Hair pigment / gray-hair delay Mouse work highlighted in science digests found oral and topical luteolin preserved follicle–melanocyte stem-cell communication and reduced graying more than several other antioxidants. Human evidence is absent. #### Exercise performance and body composition An ongoing trial is testing 100 mg daily luteolin in athletes for metabolic gene expression, performance, and body composition. Proposed mechanisms include AMPK-linked energy sensing and modulation of muscle and fat gene programs, but these remain unconfirmed in finished human outcome data. Results are not yet available, so evidence grading stays at hypothesis level only. ## Benefit-Modifying Factors - **Baseline inflammatory burden:** Individuals with higher systemic or neuroinflammation (post-viral syndromes, metabolic syndrome, mast-cell activation phenotypes) may show clearer symptomatic change than already low-inflammation healthy adults. - **Baseline biomarker levels:** Higher baseline hs-CRP (high-sensitivity C-reactive protein; a blood marker of systemic inflammation) or other inflammatory markers may identify people more likely to notice anti-inflammatory effects; very low baseline inflammatory labs make large subjective gains less likely. - **Formulation and absorption:** Benefit signal in practice depends heavily on bioavailable forms (liposomal, phospholipid complexes, PEA co-ultramicronized products) versus poorly absorbed bulk powder. - **Sex-based differences:** Human sex-stratified efficacy data for luteolin are sparse; estrogenic pathway interactions and CYP/UGT differences could theoretically modify exposure, but clinical confirmation is limited. - **Age:** Older adults with higher inflammatory tone or post-infectious sensory/cognitive sequelae are the populations best represented in PEA–luteolin trials; healthy young adults have little outcome data. - **Genetic polymorphisms:** Variants in UGT and SULT conjugating enzymes, CYP3A4/CYP1A2 activity, and OATP transporters may alter exposure; no validated pharmacogenetic dosing algorithm exists for luteolin. - **Pre-existing conditions:** Concurrent neuroinflammatory, allergic, or metabolic disease may amplify perceived benefit; advanced organ failure changes risk–benefit (see Risks and Contraindications). ## Potential Risks & Side Effects ### Medium 🟥 🟥 #### Gastrointestinal discomfort Mild nausea, abdominal discomfort, or loose stools are the most commonly mentioned tolerability issues with oral flavonoids and combination PEA–luteolin products. Symptoms are usually dose-related and reverse when the dose is lowered or stopped. They appear more often when starting high doses of poorly tolerated bulk powders than with lower starting doses of characterized formulations. **Magnitude:** Generally uncommon at studied doses (e.g., PEA 700 mg + luteolin 70 mg twice daily, or luteolin 100–500 mg/day range in trials); exact incidence not consistently reported across products. #### Drug–metabolizing enzyme interactions In vitro, luteolin can inhibit CYP3A4, CYP1A2, CYP2C9, and certain OATP transporters; conjugates show weaker CYP effects. This raises theoretical risk of altered levels of narrow-therapeutic-index drugs (e.g., some immunosuppressants, certain cancer therapies, warfarin-class anticoagulants). Clinical interaction studies measuring human AUC (area under the concentration–time curve; a measure of total drug exposure) at supplement doses are scarce, so the risk remains theoretical until quantified. **Magnitude:** Not quantified in available studies. ### Low 🟥 #### Progesterone / endocrine pathway interference Some experimental reports suggest luteolin may interfere with progesterone receptor–related signaling or steroid pathways in vitro. Human endocrine disruption at supplement doses is not demonstrated but is a watchpoint for pregnancy planning and hormone therapy in clinical populations. **Magnitude:** Not quantified in available studies. #### High-dose organ toxicity (animal) Rodent data show good margins at moderate doses; higher exposures (e.g., hundreds of mg/kg in mice) have been linked to liver/kidney stress and in vitro DNA-damage (genotoxicity) signals at high micromolar concentrations. Human supplemental doses are far lower on a mg/kg basis but long-term high-dose human toxicology is incomplete. **Magnitude:** Animal LD50 (median lethal dose; the dose that kills 50% of animals in a toxicity study) and organ-toxicity thresholds are high relative to typical human supplemental intake; human long-term toxicity rates unknown. #### Contaminated or mislabeled products Industry quality variability, documented in expert commentary on commercial luteolin, could introduce heavy metals, wrong plant fractions, or under-dosed actives. This is a product-quality risk rather than an inherent toxicity of pure luteolin. Independent identity and contaminant testing reduce but do not eliminate the problem when labels are inaccurate. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Off-target immune suppression with aggressive multi-agent combinations Theoretically, combining multiple strong mast-cell stabilizers, high-dose flavonoids, and immunosuppressive drugs could blunt needed immune responses. The concern is mechanistic rather than drawn from controlled trials of luteolin alone. Clinical reports specific to luteolin documenting clinically meaningful immune suppression from concurrent multi-agent combinations are lacking. ## Risk-Modifying Factors - **Genetic polymorphisms:** Slow or fast CYP3A4/UGT metabolizer status may change exposure to luteolin and to co-administered drugs; no routine clinical test panel is validated specifically for luteolin. - **Baseline liver and kidney function:** Impaired hepatic conjugation or reduced renal clearance of conjugates could raise exposure; elevated baseline ALT/AST (alanine and aspartate aminotransferases; liver enzymes) or reduced eGFR (estimated glomerular filtration rate; a kidney-function estimate) warrants caution and monitoring. - **Sex-based differences:** Limited data; pregnancy and lactation are special populations (avoid; see Contraindications) rather than well-characterized differential risk sexes in healthy adults. - **Pre-existing conditions:** Active peptic disease may worsen GI (gastrointestinal) side effects; polypharmacy with CYP3A4/CYP1A2 substrates increases interaction risk; hormone-sensitive conditions warrant caution given experimental endocrine pathway findings. - **Age:** Older adults often take more interacting medications and have reduced hepatic reserve; start-low strategies and medication review matter more than age alone. ## Key Interactions & Contraindications - **CYP3A4 substrate drugs (e.g., midazolam, certain statins, some calcium-channel blockers, selected immunosuppressants such as tacrolimus/cyclosporine):** Severity — caution / monitor. Consequence — possible increased drug exposure and adverse effects. Mitigation — medication review; avoid unsupervised high-dose luteolin with narrow-index CYP3A4 substrates. - **CYP1A2 substrates (e.g., caffeine, tizanidine, theophylline, some antipsychotics):** Severity — caution. Consequence — altered stimulant or drug levels. Mitigation — watch for exaggerated caffeine effects; clinician review if on tizanidine or theophylline. - **CYP2C9 substrates (e.g., warfarin, some NSAIDs [nonsteroidal anti-inflammatory drugs], sulfonylureas):** Severity — caution / monitor. Consequence — theoretical change in anticoagulant or glycemic effect. Mitigation — INR (international normalized ratio; a blood-clotting measure used to monitor warfarin) monitoring if on warfarin when starting or stopping luteolin. - **OATP1B1 / OATP2B1 substrates (e.g., certain statins):** Severity — caution. Consequence — altered hepatic uptake of co-medications. Mitigation — monitor for statin-related muscle symptoms if combined. - **Other flavonoids and mast-cell stabilizers (quercetin, apigenin, multi-flavonoid luteolin combinations, cromolyn, high-dose PEA):** Severity — additive effect / monitor. Consequence — greater anti-inflammatory or GI load. Mitigation — avoid redundant high-dose multi-flavonoid combinations without a reason. - **Sedating or CNS-active agents (central nervous system–active):** Severity — generally low known interaction, monitor. Consequence — theoretical additive calming or cognitive change. Mitigation — introduce one change at a time. - **Hormone therapies / progesterone pathways:** Severity — caution (experimental). Consequence — uncertain endocrine interaction. Mitigation — specialist input if on complex hormone regimens. - **Populations who should avoid or use only under specialist care:** - Pregnancy and breastfeeding (insufficient safety data; avoid). - Children except within research or specialist protocols (most adult optimization data do not apply). - Known allergy to luteolin-containing plants or product excipients. - Advanced hepatic failure (Child-Pugh Class C) or severe renal impairment without specialist oversight. - Concurrent narrow-therapeutic-index CYP3A4/CYP1A2/CYP2C9 drugs without monitoring plan. - Active chemotherapy or targeted cancer therapy without oncology approval (interaction and efficacy unknown). ## Risk Mitigation Strategies - **Start low, titrate:** Begin at the low end of common supplemental ranges (e.g., 50–100 mg elemental luteolin from a bioavailable form once daily) for 1–2 weeks before increasing, to reduce GI intolerance. - **Prefer characterized formulations:** Use third-party–tested products with stated luteolin content, or PEA–luteolin products used in trials (e.g., ~70 mg luteolin with 700 mg PEA twice daily when that indication is the goal), rather than untested bulk powders. - **Medication reconciliation:** Before starting, list all prescription, OTC (over-the-counter), and supplement agents; flag CYP3A4, CYP1A2, CYP2C9, and OATP substrates for clinician review to reduce interaction risk. - **Take with food containing fat:** Improves comfort and may aid absorption of lipophilic flavonoid forms; mitigates empty-stomach nausea. - **Limit redundant flavonoid megadoses:** Cap total high-dose multi-flavonoid combinations to lower GI and interaction burden. - **Lab-backed monitoring in higher-risk users:** Baseline and follow-up liver enzymes and, if on warfarin, INR checks after initiation mitigate undetected hepatic stress or anticoagulant shifts. - **Pause for acute illness or new prescriptions:** Temporarily stop when starting new narrow-index drugs or during acute hepatitis until a plan is clear. ## Therapeutic Protocol Protocols used in research and specialist practice vary; there is no single universal “longevity dose.” - **Common research / specialty ranges:** Isolated luteolin supplements in human protocols often fall around 100–500 mg/day (e.g., 100 mg daily in an athletic metabolic trial; 250 mg twice daily for two weeks in a memory crossover trial). PEA–luteolin neuroinflammation protocols frequently use ultramicronized PEA 700 mg + luteolin 70 mg once or twice daily for weeks to months. - **Competing approaches:** (1) Dietary emphasis only (celery, parsley, herbs, peppers, olive oil) — low dose, high safety, limited pharmacologic exposure. (2) Bioavailable standalone luteolin (liposomal / phytosome / enhanced-absorption) — longevity and anti-inflammatory self-experimentation focus. (3) PEA–luteolin co-ultramicronized products popularized in European ENT (ear, nose, and throat) and neurology research for post-viral smell loss and selected neurodegenerative studies. (4) Theoharides-style liposomal luteolin in olive-fruit extract historically used in autism-spectrum and mast-cell clinical series. - **Time of day:** Morning or with the largest meal is common; split dosing (twice daily) matches short half-life and was used in memory and PEA–luteolin trials. Evening dosing is acceptable if GI comfort is better; no strong circadian mandate is established. - **Half-life and dosing split:** Elimination half-life is typically a few hours for free/conjugated fractions; once-daily dosing is used for convenience with extended-release or highly bioavailable forms, while twice-daily dosing better covers the day for standard forms. - **Genetic factors:** No standard PGx-guided (pharmacogenetic; gene-based dosing) dose. Theoretically, low UGT/SULT activity could raise free luteolin; high CYP3A4 activity might alter interaction risk with other drugs more than luteolin efficacy itself. - **Sex-based considerations:** No established sex-specific dose. Pregnancy avoidance applies regardless of dose. - **Age:** Older adults may start at 50–100 mg/day bioavailable luteolin or standard PEA–luteolin single daily dosing, with slower titration and medication review. - **Baseline biomarkers:** Higher hs-CRP or symptomatic post-viral neuroinflammation may justify a time-limited therapeutic trial; very low inflammatory markers make large subjective gains less likely. - **Pre-existing conditions:** Use PEA–luteolin trial-style dosing when smell recovery is the target; use lower standalone doses for general inflammatory tone; avoid in the contraindicated groups above. ## Discontinuation & Cycling - **Duration intent:** Not inherently lifelong. Post-viral olfactory protocols are typically weeks to a few months. Longevity-oriented use is often continuous or seasonal, based on goals rather than proven necessity of indefinite use. - **Withdrawal effects:** No classic withdrawal syndrome is described; stopping usually means loss of any symptomatic benefit rather than rebound illness. - **Tapering:** Abrupt stop is generally acceptable at supplemental doses; tapering over 3–7 days is optional if high doses or multiple anti-inflammatory agents are being reduced together. - **Cycling:** Not required for receptor “reset” in the way some stimulants are cycled. Practical cycling (e.g., 8–12 weeks on, 2–4 weeks off) is sometimes used to reassess benefit and reduce cumulative polypharmacy, without strong trial evidence that cycling preserves efficacy. - **Reassessment checkpoints:** Defined stop rules (e.g., reassess at 8–12 weeks for subjective cognition/energy/smell; discontinue if no meaningful change) keep use intentional. ## Sourcing and Quality - **Purity and identity:** Look for products stating pure luteolin (not only “flavonoid complex”) with quantitative milligram content per serving and ideally HPLC (high-performance liquid chromatography; a lab method that verifies compound identity and amount) verification. - **Third-party testing:** Prefer NSF, USP, Informed-Sport, or independent lab COAs (certificates of analysis) for identity, heavy metals, and microbial limits—especially important given published concerns about variable commercial luteolin quality. - **Formulation type:** Enhanced-absorption forms (liposomal, phytosome/phospholipid, micronized, PEA co-ultramicronized) are preferred when systemic exposure is the goal; bulk crystalline powder alone is poorly absorbed. - **PEA–luteolin products:** For indications studied with CoUltraPEALut / um-PEA-LUT, match the researched ratio and micronization claims when possible rather than mixing separate PEA and luteolin arbitrarily. - **Brand examples (illustrative, not endorsements):** Research-linked PEA–luteolin medical foods/supplements used in European trials; liposomal luteolin products associated with mast-cell research; major catalog brands offering third-party–tested luteolin. Verify current COAs rather than relying on brand reputation alone. - **Storage:** Cool, dry, dark conditions; follow label for oil-based softgels. ## Practical Considerations - **Time to effect:** Anti-inflammatory or subjective “brain fog” changes, when they occur, are often discussed over 2–8 weeks. PEA–luteolin smell recovery trials typically evaluate over several weeks of combined training. Longevity biomarker shifts, if any, would require months and are unproven. - **Common pitfalls:** Using poorly absorbed powder and concluding “luteolin does nothing”; combining many flavonoids without tracking dose; expecting cancer or lifespan outcomes from short self-experiments; ignoring drug-interaction review; treating PEA–luteolin trial results as proof of isolated luteolin at any dose. - **Regulatory status:** Sold as a dietary supplement / food component in many jurisdictions, not an FDA (U.S. Food and Drug Administration)–approved drug for any disease. Disease claims (treat COVID, cure dementia, treat cancer) are not authorized supplement claims. - **Cost and access:** Enhanced-absorption and PEA combination products cost more than bulk powder; still generally accessible online and in specialty shops compared with prescription agents. Trial-matched medical-food products may be harder to source outside certain countries. ## Interaction with Foundational Habits - **Sleep:** Direction — generally neutral to possibly indirect benefit via reduced inflammatory discomfort. Mechanism — no strong sedative profile at usual doses; lowering neuroinflammation could support sleep quality in inflamed individuals. Practical note — if evening GI upset occurs, shift dose earlier. - **Nutrition:** Direction — potentiating with a polyphenol-rich Mediterranean-style pattern; food sources add small baseline intake. Mechanism — fat-containing meals may aid absorption of lipophilic forms; extreme low-fat meals may reduce uptake. Practical note — celery, parsley, thyme, peppers, and olive oil contribute dietary luteolin but usually far below supplemental milligram doses. - **Exercise:** Direction — theoretically complementary (anti-inflammatory recovery) without established performance enhancement yet. Mechanism — AMPK and oxidative-stress pathways overlap exercise adaptations; whether luteolin blunts or aids training adaptations is unproven. Practical note — an athletic trial of 100 mg daily is underway; until results, avoid assuming performance-enhancing (ergogenic) benefit. - **Stress management:** Direction — indirect, possibly potentiating subjective resilience if mast-cell/histamine reactivity is part of the stress phenotype. Mechanism — HPA-axis (hypothalamic–pituitary–adrenal axis; the body’s main stress-hormone circuit) data are limited; primary rationale is inflammatory-tone reduction rather than direct anxiety relief (anxiolysis). Practical note — not a substitute for sleep, therapy, or proven stress tools. ## Monitoring Protocol & Defining Success Baseline evaluation before a structured trial includes a symptom journal (energy, cognition, smell if relevant, allergic symptoms, GI comfort), medication list, and optional labs if polypharmacy or metabolic risk is present. Ongoing monitoring for a time-limited trial: check-in at 2 weeks (tolerability), 4–8 weeks (early benefit), and 12 weeks (continue vs. stop decision), with labs every 3–6 months if use becomes long-term or if liver/drug-interaction risk is present. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | hs-CRP | <1.0 mg/L (functional often <0.5–1.0) | Tracks systemic inflammatory tone that luteolin aims to influence | hs-CRP = high-sensitivity C-reactive protein (inflammation marker); non-fasting acceptable; interpret with illness; conventional labs often flag only higher cutoffs | | ALT / AST | ALT ideally <25–30 U/L (sex-dependent functional targets); avoid rising trends | Hepatic safety with polyphenols and polypharmacy | ALT/AST = alanine and aspartate aminotransferases (liver enzymes); fasting not required; compare to personal baseline | | GGT | Lower within lab range; functional often <20–30 U/L | Extra hepatic/oxidative stress context | GGT = gamma-glutamyl transferase (liver/biliary enzyme); useful if alcohol use or metabolic syndrome present | | eGFR / creatinine | eGFR ≥90 mL/min/1.73 m² preferred; investigate sustained decline | Baseline renal clearance context | eGFR = estimated glomerular filtration rate (kidney-function estimate); age-adjust expectations; not a direct luteolin target | | Fasting glucose / HbA1c | Glucose ~70–90 mg/dL; HbA1c ~4.8–5.3% functional targets (individualize) | Metabolic context if metabolic benefit is a goal | Fasting for glucose; HbA1c no fasting; interpret with personal baseline and illness | | CBC | Within lab reference; watch unexpected cytopenias (low blood cell counts) | General safety screen | CBC = complete blood count; low yield for luteolin specifically | | INR (if on warfarin) | Per anticoagulation clinic target | Detect CYP2C9-related interaction | INR = international normalized ratio (warfarin clotting measure); recheck after start/stop/dose change | Qualitative markers: - Morning cognitive clarity and afternoon mental fatigue - Smell identification/threshold (if post-viral indication) - Allergic or histamine-type symptom frequency - Training recovery and joint comfort - GI tolerance and stool pattern - Subjective sense that benefits justify continued cost and daily supplement burden Success for a longevity-oriented user is typically defined as improved inflammatory or cognitive symptoms without lab or interaction problems—not as a proven change in lifespan. ## Emerging Research - **PEA–luteolin in frontotemporal dementia:** A completed Phase 2 randomized trial ([NCT04489017](https://clinicaltrials.gov/study/NCT04489017)) of ultramicronized PEA combined with luteolin in frontotemporal dementia; peer-reviewed Phase 2 analyses (e.g., [Assogna et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40046339/)) explore cognitive and synaptic plasticity outcomes and could strengthen or limit neuroprotective claims. - **Athletic metabolism trial:** [NCT07280520](https://clinicaltrials.gov/study/NCT07280520) is evaluating 100 mg daily luteolin for 12 weeks on myocyte/adipocyte gene expression (MEF2 [myocyte enhancer factor 2; a muscle gene-expression regulator], SREBP-1 [sterol regulatory element-binding protein 1; a fat-metabolism gene regulator]), performance, and body composition in male athletes—relevant to healthy-user metabolic claims. - **Memory in healthy adults:** [NCT06047899](https://clinicaltrials.gov/study/NCT06047899) tested 250 mg luteolin twice daily for two weeks on memory in healthy subjects; results will clarify short-term cognitive effects outside disease states. - **Schizophrenia adjunct:** [NCT05204407](https://clinicaltrials.gov/study/NCT05204407) completed a luteolin trial in people with schizophrenia, probing psychiatric and inflammatory endpoints. - **Post-surgical cognition in older adults:** [NCT07681063](https://clinicaltrials.gov/study/NCT07681063) plans PEA/luteolin around cardiac surgery for postoperative cognitive dysfunction risk—could expand geriatric neuroinflammation use cases or show null results. - **Bioavailability engineering:** Human data on formulations raising absorption many-fold (Life Extension and related industry reports; nano/phospholipid academic reviews such as [Shang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37986608/)) may change effective dosing and, with it, both benefit and interaction risk. - **Oncology translation gap:** Narrative and systematic preclinical anticancer reviews (e.g., [Shi et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38088265/), [Mishan et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33720053/)) continue to outpace clinical trials; negative or null human oncology results would appropriately down-weight speculative cancer claims. ## Conclusion Luteolin is a dietary flavone with deep laboratory support as an anti-inflammatory, antioxidant, and mast-cell–stabilizing compound (mast cells release histamine and other inflammatory mediators). For health- and longevity-focused adults, the practical evidence base is uneven: the clearest human signal is for palmitoylethanolamide–luteolin combinations plus smell training after viral smell loss, with emerging but still limited data in selected brain-inflammation and cognitive settings. Standalone luteolin for general longevity, metabolic optimization, heart protection, or cancer risk reduction remains grounded mainly in animal and cell work, not large outcome trials. Safety at usual supplemental intakes appears favorable, with stomach or bowel discomfort the main day-to-day issue and drug-metabolizing enzyme and transporter interactions the main theoretical concern—especially for people on multiple medications. Poor native absorption means formulation quality is not a minor detail; it largely determines whether meaningful amounts reach the bloodstream. Quality variation in commercial products is a documented practical problem. Overall, luteolin sits in the “biologically plausible, clinically under-proven for broad longevity claims” category. Its role is best understood as a targeted anti-inflammatory tool with a growing but still specialized clinical footprint, not as a fully validated lifespan drug. Palmitoylethanolamide–luteolin neurology studies, healthy-volunteer cognitive trials, and high-absorption formulations are active lines of evidence that continue to shape how strong those claims can be. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**